Coherus BioSciences Management to Present at the 2018 Cantor Global Healthcare Conference in October
September 17 2018 - 7:00AM
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that
senior management will be presenting at the 2018 Cantor Global
Healthcare Conference being held in New York on Tuesday, October 2,
2018 at 8:00 am ET.
The audio portion of the presentation will be available on the
investors page of the Coherus BioSciences website at
http://investors.coherus.com.
About Coherus BioSciences, Inc.Coherus is a
leading biosimilar company that develops and commercializes
high-quality therapeutics for major regulated markets. Biosimilars
are intended for use in place of existing, branded biologics to
treat a range of chronic and often life-threatening diseases, with
the potential to reduce costs and expand patient access. Composed
of a team of proven industry veterans with world-class expertise in
process science, analytical characterization, protein production,
sales & marketing and clinical-regulatory development, Coherus
is positioned as a leader in the global biosimilar marketplace.
Coherus is advancing three late-stage clinical products towards
commercialization, UDENYCA™ (pegfilgrastim-cbqv), CHS-1420
(adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as
well as developing a robust pipeline of future products in
ophthalmology (including CHS-3351, a ranibizumab biosimilar, and
CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small
molecule for nonalcoholic steatohepatitis (NASH) and multiple
sclerosis. For additional information, please visit
www.coherus.com.
CONTACT:Jean-Frédéric Viret, Ph.D.Chief Financial OfficerCoherus
BioSciences, Inc.jviret@coherus.com+1 (650) 649-3546
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2024 to May 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From May 2023 to May 2024